Shahrzad Ghazisaeidi

Shahrzad Ghazisaeidi

Auto-generated profile, based on publicly available information

Shahrzad Ghazisaeidi

University of Toronto

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
KHKatherine Halievski
Katherine Halievski
SGShahrzad Ghazisaeidi
Shahrzad Ghazisaeidi
MSMichael W. Salter
Michael W. Salter
For over two decades, purinergic signaling in microglia has persisted in the spotlight as a major pathomechanism of chronic pain. Of the many purinoreceptors, the P2X4R of the ionotropic family, has a well-described causal role underlying chronic neuropathic pain. This review will briefly examine microglial P2X4R signaling in the spinal cord as it relates to chronic pain through a historical lens, followed by a more in-depth examination of recent work, which has revealed major sex differences. We also discuss the generalizability of sex differences in microglial and P2X4R signaling in other pain conditions as well as in nonspinal regions. Finally, we speculate on remaining gaps in the literature as well as what can be done to address them with the ultimate goal of using our collective knowledge to treat chronic pain effectively and in both sexes. SIGNIFICANCE STATEMENT Effective treatments are lacking for chronic pain sufferers, and this may be explained by the vast sex differences underlying chronic pain mechanisms. In this minireview, we focus on the roles of microglia and P2X4R in chronic pain, with specific attention to the circumstances under which these pathomechanisms differ between males and females. By delineating the ways in which pain occurs differently between the sexes, we can start developing successful therapies for all.

27 January 2023 in Science Advances
Verified
Journal Article
Closed access
STShogo Tsujikawa
Shogo Tsujikawa
KDKaitlyn E. DeMeulenaere
Kaitlyn E. DeMeulenaere
MCMaria V. Centeno
Maria V. Centeno
SGShahrzad Ghazisaeidi
Shahrzad Ghazisaeidi
MMMegan E. Martin
Megan E. Martin
MPMurali Prakriya
Murali Prakriya
Microglia are important mediators of neuroinflammation, which underlies neuropathic pain. However, the molecular checkpoints controlling microglial reactivity are not well-understood. Here, we investigated the role of Orai1 channels for microglia-mediated neuroinflammation following nerve injury and find that deletion of Orai1 in microglia attenuates Ca 2+ signaling and the production of inflammatory cytokines by proalgesic agonists. Conditional deletion of Orai1 attenuated microglial proliferation in the dorsal horn, spinal cytokine levels, and potentiation of excitatory neurotransmission following peripheral nerve injury. These cellular effects were accompanied by mitigation of pain hyperalgesia in microglial Orai1 knockout mice. A small-molecule Orai1 inhibitor, CM4620, similarly mitigated allodynia in male mice. Unexpectedly, these protective effects were not seen in female mice, revealing sexual dimorphism in Orai1 regulation of microglial reactivity and hyperalgesia. Together, these findings indicate that Orai1 channels are key regulators of the sexually dimorphic role of microglia for the neuroinflammation that underlies neuropathic pain.

27 July 2023 in British Journal of Pharmacology
Verified
Journal Article
Open access
SGShahrzad Ghazisaeidi
Shahrzad Ghazisaeidi
MMMilind M. Muley
Milind M. Muley
YTYuShan Tu
YuShan Tu
DFDavid P. Finn
David P. Finn
MKMahshad Kolahdouzan
Mahshad Kolahdouzan
MSMichael W. Salter
Michael W. Salter
Background and Purpose: Chronic pain is a devastating problem affecting one in five individuals around the globe, with neuropathic pain the most debilitating and poorly treated type of chronic pain. Advances in transcriptomics have contributed to cataloguing diverse cellular pathways and transcriptomic alterations in response to peripheral nerve injury but have focused on phenomenology and classifying transcriptomic responses.Experimental approach: To identifying new types of pain‐relieving agents, we compared transcriptional reprogramming changes in the dorsal spinal cord after peripheral nerve injury cross‐sex and cross‐species, and imputed commonalities, as well as differences in cellular pathways and gene regulation.Key Results: We identified 93 transcripts in the dorsal horn that were increased by peripheral nerve injury in male and female mice and rats. Following gene ontology and transcription factor analyses, we constructed a pain interactome for the proteins encoded by the differentially expressed genes, discovering new, conserved signalling nodes. We investigated the interactome with the Drug‐Gene database to predict FDA‐approved medications that may modulate key nodes within the network. The top hit from the analysis was fostamatinib, the molecular target of which is the non‐receptor spleen associated tyrosine kinase (Syk), which our analysis had identified as a key node in the interactome. We found that intrathecally administrating the active metabolite of fostamatinib, R406 and another Syk inhibitor P505‐15, significantly reversed pain hypersensitivity in both sexes.Conclusions and Implications: Thus, we have identified and shown the efficacy of an agent that could not have been previously predicted to have analgesic properties.

6 January 2026 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
BKBharti Kukreja
Bharti Kukreja
SJShin Jeon
Shin Jeon
WCWuxinhao Cao
Wuxinhao Cao
BRBianca Rusu
Bianca Rusu
CHCamille F. Harrison
Camille F. Harrison
BKBrian T. Kalish
Brian T. Kalish

15 September 2022
Verified
Preprint
Open access
PDF file
SGShahrzad Ghazisaeidi
Shahrzad Ghazisaeidi
MMMilind Muley
Milind Muley
YTYuShan Tu
YuShan Tu
MKMahshad Kolahdouzan
Mahshad Kolahdouzan
ASAmeet Sengar
Ameet Sengar
MSMichael Salter
Michael Salter
Background and Purpose: Chronic pain is a devastating problem affecting 1 in 5 individuals around the globe, with neuropathic pain the most debilitating and poorly treated type of chronic pain. Advances in transcriptomics and data mining have contributed to cataloging diverse cellular pathways and transcriptomic alterations in response to peripheral nerve injury but have focused on phenomenology and classifying transcriptomic responses. Experimental approach: Here, with the goal of identifying new types of pain-relieving agents, we compared transcriptional reprogramming changes in the dorsal spinal cord after peripheral nerve injury cross-sex and cross-species and imputed commonalities, as well as differences in cellular pathways and gene regulation. Key Results : We identified 93 transcripts in the dorsal horn that were increased by peripheral nerve injury in male and female mice and rats. Following gene ontology and transcription factor analyses, we constructed a pain interactome for the proteins encoded by the differentially expressed genes, discovering new, conserved signaling nodes. We interrogated the interactome with the Drug-Gene database to predict FDA-approved medications that may modulate key nodes within the network. The top hit from the analysis was fostamatinib, the molecular target of which is the non-receptor tyrosine kinase Syk, which our analysis had identified as a key node in the interactome. Conclusions & Implications : We found that intrathecally administrating the active metabolite of fostamatinib, R406, significantly reversed pain hypersensitivity in both sexes. Thus, we have identified and shown the efficacy of an agent that could not have been previously predicted to have analgesic properties.

31 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SGShahrzad Ghazisaeidi
Shahrzad Ghazisaeidi
MMMilind M. Muley
Milind M. Muley
YTYuShan Tu
YuShan Tu
MKMahshad Kolahdouzan
Mahshad Kolahdouzan
ASAmeet S. Sengar
Ameet S. Sengar
MSMichael W. Salter
Michael W. Salter
Chronic pain is a devastating problem affecting 1 in 5 individuals around the globe, with neuropathic pain the most debilitating and poorly treated type of chronic pain. Advances in transcriptomics and data mining have contributed to cataloging diverse cellular pathways and transcriptomic alterations in response to peripheral nerve injury but have focused on phenomenology and classifying transcriptomic responses. Here, with the goal of identifying new types of pain-relieving agents, we compared transcriptional reprogramming changes in the dorsal spinal cord after peripheral nerve injury cross-sex and cross-species and imputed commonalities, as well as differences in cellular pathways and gene regulation. We identified 93 transcripts in the dorsal horn that were increased by peripheral nerve injury in male and female mice and rats. Following gene ontology and transcription factor analyses, we constructed a pain interactome for the proteins encoded by the differentially expressed genes, discovering new, conserved signaling nodes. We interrogated the interactome with the Drug-Gene database to predict FDA-approved medications that may modulate key nodes within the network. The top hit from the analysis was fostamatinib, the molecular target of which is the non-receptor tyrosine kinase Syk, which our analysis had identified as a key node in the interactome. We found that intrathecally administrating the active metabolite of fostamatinib, R406, significantly reversed pain hypersensitivity in both sexes. Thus, we have identified and shown the efficacy of an agent that could not have been previously predicted to have analgesic properties. One sentence summary: Unbiased approach to predicting safe therapies for neuropathic pain